Clinical trials: Myelodysplasia
Chronic Myeloproliferative Disorders, Infection
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or…
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT01101412
- Testing
- Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole
- Sponsor
- M.D. Anderson Cancer Center
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ipilimumab when given together with decitabine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that has returned after a period of…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT02890329
- Testing
- Decitabine, Ipilimumab
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to find out the maximum tolerated dose (MTD) of the combined therapy of lenalidomide (Revlimid®) and Granulocyte/macrophage colony stimulating factor and CD40 Ligand expressed in the K562 cell line…
- Trial name
- NCT00840931
- Testing
- lenalidomide, bystander vaccine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelofibrosis, Chronic Myelomonocytic Leukemia
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse.
- Conditions
- Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT05233618
- Testing
- Tagraxofusp
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Karen Ballen, MD
Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder
- Trial name
- NCT02861417
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00024050
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes, Multiple Myeloma
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or…
- Conditions
- Myelodysplastic Syndromes, Multiple Myeloma, Anemia
- Trial name
- LIMBER (NCT04582539)
- Testing
- INCB000928
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 22 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
This study is a Phase II, single arm, open label multicenter trial designed to investigate the use of haploidentical donor derived NK cells (K-NK002) for the treatment of patients with high-risk acute myeloid leukemia (AML) or…
- Trial name
- NCT04395092
- Testing
- K-NK002, Conditioning Regimen, HaploBMT
- Where
- 2 sites in United States
- Sponsor
- Kiadis Pharma
Myelodysplastic Syndromes (MDS)
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
The primary objective of this study is to describe the response to treatment with biosimilar EPO alpha in MDS patients who had already been treated with "originator" EPO alpha and were responsive, and in patients who started…
- Trial name
- NCT06764511
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Myelodysplastic Syndromes
Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial
Three recent prospective "transplant/no transplant" studies concluded to an advantage of OS with transplantation in patients with high or intermediate-2 IPSS risk (not significant in Kröger's study).
- Trial name
- FIRST ALLO MDS (NCT06235398)
- Testing
- Hematopoietic stem-cell transplantation
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Dose-reduced Versus Standard Conditioning in MDS/sAML
In this trial dose reduced conditioning is compared to standard conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML.
- Trial name
- RICMAC (NCT01203228)
- Testing
- Reduced Intensity Conditioning, Myeloablative conditioning
- Where
- 14 sites in Germany, Italy and 2 more
- Volunteers
- 129 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Advanced Hematologic Malignancies, Leukemia
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid…
- Conditions
- Advanced Hematologic Malignancies, Leukemia, Preleukemia
- Trial name
- NCT00943592
- Testing
- Clofarabine, Melphalan, Campath
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Chicago
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
This phase II trial is studying the side effects and how well giving fludarabine phosphate, busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant, tacrolimus, and methotrexate works in treating…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01056614
- Testing
- fludarabine phosphate, busulfan, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Bone Marrow Failure Disorders, VEXAS Syndrome
Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
STUDY DESCRIPTION: Bone marrow failure can result from immune mediated attack on stem cells or from inherited genetic defects such as telomere biology disorders or Fanconi anemia.
- Conditions
- Bone Marrow Failure Disorders, VEXAS Syndrome, Hemoglobinurea, Paroxysmal, Myelodysplastic Syndromes
- Trial name
- NCT07102849
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Fanconi's Anemia, Myelodysplastic Syndromes
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
OBJECTIVES: I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with…
- Conditions
- Fanconi's Anemia, Myelodysplastic Syndromes, Leukemia, Nonlymphocytic, Acute, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00005892
- Testing
- cyclophosphamide, Allogeneic Bone Marrow Transplantation
- Where
- United States
- Sponsor
- Fairview University Medical Center
Leukemia
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
- Trial name
- NCT00948064
- Testing
- Vorinostat, Azacitidine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT06788509
- Testing
- JNJ-75348780, JNJ-67856633, JNJ-54179060
- Where
- 39 sites in Australia, Belgium and 13 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.